NIVEGU.KNOW BEFORE YOU FLY

THE WORLD OF AVIATION.
YOUR JOURNEY, EXPLAINED.

NASDAQ / LIVE COMPANY INTELLIGENCE

Adicet Bio, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERACET
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / ACET COVERAGE

What’s moving Adicet Bio, Inc. now

Current reporting with the operating signal separated from the noise.

01
Adicet Bio, Inc. annonce des données positives de sécurité et d’efficacité issues de l’étude de prula-cel chez des patients atteints de lupus érythémateux ...

Adicet Bio, Inc. annonce des données positives de sécurité et d’efficacité issues de l’étude de prula-cel chez des patients atteints de lupus érythémateux ...

The story matters when it changes Adicet Bio, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Adicet Bio, Inc. Announces Positive Safety And Efficacy Data From Prula-Cel Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis

Adicet Bio, Inc. Announces Positive Safety And Efficacy Data From Prula-Cel Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis

The story matters when it changes Adicet Bio, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: regulator filings, verified operating scope and liability disclosures.
03
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Investors are testing whether Adicet Bio, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Adicet Bio, Inc. Announces Pricing of Public Offering

Adicet Bio, Inc. Announces Pricing of Public Offering

The story matters when it changes Adicet Bio, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Adicet Bio, Inc. Announces Proposed Public Offering

Adicet Bio, Inc. Announces Proposed Public Offering

The story matters when it changes Adicet Bio, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest ACET filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-08-05 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-13 · Period 2026-03-31SEC ↗10-K/AAnnual financial reportFiled 2026-05-20 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-09-28 · Period 2026-09-28SEC ↗8-KMaterial company eventFiled 2026-09-08 · Period 2026-09-08SEC ↗8-KMaterial company eventFiled 2026-09-01 · Period 2026-09-01SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-29 · Period 2026-04-29SEC ↗SCHEDULE 13G/AOfficial SEC filingFiled 2026-08-14SEC ↗
EARNINGS / QUARTERLY TRACKER

Adicet Bio, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.